在轻度阿尔茨海默氏症痴呆症中的马感官刺激:一个开放式标签扩展研究
Diane Chan1,2,3, Gabrielle de Weck1, Brennan L Jackson1,4
1Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|October 25, 2025
概括
两年来每天40赫兹的视听刺激显示了阿尔茨海默病 (AD) 患者的安全性和潜在的认知益处. 一些参与者经历了阿尔茨海默氏症生物标志物的减少,这表明这种非侵入性治疗具有前景.
科学领域:
- 神经科学是一个神经科学.
- 老年学是指老年学的学科.
- 生物标志物研究 生物标志物研究
背景情况:
- 阿尔茨海默病 (AD) 构成了重大挑战,需要新的治疗策略.
- 轻度AD患者需要干预措施来减缓认知衰退并改善生活质量.
研究的目的:
- 评估每天40 Hz (马频率) 视听刺激在轻度AD患者的长期安全性和有效性.
- 评估这种干预对认知功能和AD关键生物标志物的影响.
主要方法:
- 五名轻度阿尔茨海默病患者每天接受1小时40赫兹视听刺激,持续两年.
- 评估包括脑电图 (EEG) 来测试神经引进,MRI 来测试大脑体积,动图,神经心理测试和血pTau217测量.
主要成果:
- 该干预措施是安全的,没有报告任何不良事件.
- 与对照组相比,晚期发病的AD (LOAD) 患者表现出保留的EEG引入和更好的认知得分 (MMSE,CDR,FAS).
- 两个LOAD患者的血pTau217水平显著降低 (47%和19%).
结论:
- 长期40赫兹视听刺激似乎是安全的和可行的轻度AD.
- 该疗法可能会为认知和生物标志物带来好处,特别是在LOAD患者中.
- 这项试点研究是首次将持续40赫兹治疗与阿尔茨海默病生物标志物变化联系起来,需要进一步调查.
相关概念视频
01:22Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K